Cushing’s syndrome Market Size | Cushing’s syndrome Market Growth Analysis As per the National Organization for Rare Disorders, although it may occur in children, Cushing’s syndrome most commonly affects adults between the ages of 25 to 40. Similarly, as per the Orphanet, the prevalence of endogenous Cushing’s Syndrome (CS) is 1/26,000 and, in the EU, it has an annual prevalence of 1/1,400,000-1/400,000, with a peak prevalence at 25-40 years of age. The dynamics of Cushing’s Syndrome market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and also expects the launch of emerging therapies during the forecast period. Some of the key Cushing's Syndrome companies involved in the therapeutics development includes Recordati, Corcept Therapeutics, Millendo Therapeutics, Cortendo, SteroTherapeutics, HRA Pharma, and many others



